50 results on '"Al-Kadhimi, Zaid"'
Search Results
2. Highlights into historical and current immune interventions for cancer
3. Enrichment of innate immune cells from PBMC followed by triple cytokine activation for adoptive immunotherapy
4. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy
5. Low‐dose decitabine plus venetoclax as post‐transplant maintenance for high‐risk myeloid malignancies.
6. Survival of Older Adults With Newly Diagnosed Acute Myeloid Leukemia: Effect of Using Multiagent Versus Single-agent Chemotherapy
7. Effects of Obesity on Overall Survival of Adults With Acute Myeloid Leukemia
8. Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
9. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
10. Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
11. Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease
12. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
13. Targeting CD138−/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity
14. Incidence, Risk Factors, and Outcome of Cytomegalovirus Viremia and Gastroenteritis in Patients with Gastrointestinal Graft-versus-Host Disease
15. High Incidence of Severe Acute Graft-Versus-Host Disease with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic Transplantation Patients
16. CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma
17. A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Normal Renal Function
18. Anti-Thymocyte Globulin (Thymoglobulin), Tacrolimus, and Sirolimus as Acute Graft-versus-Host Disease Prophylaxis for Unrelated Hematopoietic Stem Cell Transplantation
19. Role of myeloid-derived suppressor cells in tumor recurrence.
20. Melphalan 180 mg/m2 Can Be Safely Administered As Conditioning Regimen before an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 mL/min/1.73 m2 or Lower with Use of Palifermin for Cytoprotection: Results of a Phase I Trial
21. Nonabsorbable Corticosteroids Use in the Treatment of Gastrointestinal Graft-versus-Host Disease
22. Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant
23. Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma
24. Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial
25. Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors
26. Integrating geriatric assessment and genetic profiling to personalize therapy selection in older adults with acute myeloid leukemia.
27. HIV infection and antiphospholipid antibody: literature review and link to the antiphospholipid syndrome
28. The Missing LNK: Evolution from Cytosis to Chronic Myelomonocytic Leukemia in a Patient with Multiple Sclerosis and Germline SH2B3 Mutation.
29. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1–specific CTLs by cotransfer of T cells modified to present influenza MP1
30. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease
31. Lambert–Eaton syndrome with large-cell neuroendocrine carcinoma of the lung
32. Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies
33. Case Report: HIV Infection and Antiphospholipid Antibody: Literature Review and Link to the Antiphospholipid Syndrome
34. S248: SIERRA TRIAL RESULTS WITH A TARGETED RADIOTHERAPY, IOMAB‐B, A MYELOABLATIVE CONDITIONING WITH REDUCED INTENSITY TOLERABILITY YIELDS HIGH CR, LONG TERM SURVIVAL IN HSCT INELIGIBLE ACTIVE R/R AML.
35. Effects of Distance From Academic Cancer Center on Overall Survival of Acute Myeloid Leukemia: Retrospective Analysis of Treated Patients.
36. Prevalence and effects of polypharmacy on overall survival in acute myeloid leukemia.
37. Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients.
38. PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients.
39. Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations.
40. A phase II study of tacrolimus and thymoglobulin as graft‐versus‐host‐disease prophylaxis in related donor allogeneic hematopoietic cell transplantation.
41. Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma.
42. Enhancing siRNA effects in T cells for adoptive immunotherapy.
43. Effects of Distance from Academic Cancer Center on Overall Survival in Acute Myeloid Leukemia.
44. Usefulness of Charlson Comorbidity Index to Predict Early Mortality and Overall Survival in Older Patients With Acute Myeloid Leukemia.
45. Melphalan 180 mg/m2 Can Be Safely Administered As Conditioning Regimen before an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 mL/min/1.73 m2 or Lower with Use of Palifermin for Cytoprotection: Results of a Phase I Trial
46. Feasibility of Administering Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Ongoing Phase III Sierra Trial Experience at 6 Study Sites.
47. Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Allogeneic Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial
48. 166 - Assessing Individual Comorbidities in Elderly Non-Hodgkin Lymphoma (NHL) Patients Undergoing Autologous Stem Cell Transplant (ASCT).
49. 445 - Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD).
50. Tailored Post-Transplant Maintenance with Tyrosine Kinase Inhibitors for High-Risk Philadelphia Chromosome-Positive Leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.